AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of Risankizumab in patients with moderate to severe ulcerative colitis. This real-world study aims to assess ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled ‘A ...

Patients with psoriasis who show an early response to the biologics risankizumab or guselkumab are more likely to have a long ...

After six months of treatment, medicines called 'biologics' seem to work best to clear raised patches of psoriasis on the skin. Longer studies are needed to assess the benefits and potential unwanted ...

The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK ...